Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Phase I Study to Assess and Compare the Pharmacokinetic Parameters After Single Oral Administration of MD1003 100 mg in Hepatic Impaired Patients and Healthy Subjects With Normal Hepatic Function

NCT04252417 is registered in ClinicalTrials.gov with MedDay Pharmaceuticals SA as lead sponsor.

NCT NCT04252417
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04252417 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Phase I Study to Assess and Compare the Pharmacokinetic Parameters After Single Oral Administration of MD1003 100 mg in Hepatic Impaired Patients and Healthy Subjects With Normal Hepatic Function
Lead sponsor
MedDay Pharmaceuticals SA
Phase
Phase 1
Overall status
Terminated
Start date
October 11, 2019
Completion date
March 17, 2020
Enrollment
15 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers, hepatic impairment of moderate child pugh category